153171-22-3

Usage

Uses

Used in Organic Synthesis:
2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is used as a key intermediate in the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable building block for creating new molecules with specific properties and applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is used as a starting material for the development of new drugs and pharmaceuticals. Its potential biological activities, such as antimicrobial and antitumor properties, make it a promising candidate for further research and drug discovery.
Used in Pharmaceutical Industry:
2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is used as a precursor in the synthesis of various pharmaceuticals and biologically active molecules. Its versatility and potential applications in drug development make it an important compound in the pharmaceutical industry.
Used in Antimicrobial Applications:
2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione exhibits antimicrobial properties, making it a potential candidate for the development of new antimicrobial agents. It can be used in the formulation of drugs to combat bacterial infections and other microbial diseases.
Used in Antitumor Applications:
Due to its antitumor properties, 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is used in the development of new cancer treatments. It can be studied for its potential to inhibit tumor growth and progression, as well as its ability to enhance the efficacy of existing chemotherapeutic drugs.

Upstream product

• 1074-82-4 potassium phtalimide 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 85-44-9 phthalic anhydride 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 136918-14-4 phthalimide 
• 873-75-6 4-bromobenzenemethanol 
• 524-38-9 N-hydroxyphthalimide 
• 106-38-7 para-bromotoluene 
• 3959-07-7 4-Bromobenzylamine 

Downstream Products

• 1001242-92-7 2-(4-morpholin-4-ylbenzyl)-1H-isoindole-1,3(2H)-dione 
• 51980-05-3 4-allylbenzonitrile 
• 1122-91-4 4-bromo-benzaldehyde 
• 623-00-7 4-bromobenzenecarbonitrile 
• 10602-01-4 p-bromobenzaldehyde 1,3-dioxolane 
• 1222368-50-4 6-bromo-3-methyl-isoquinoline 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 1616590-38-5 (E)-3-[4-(4,4-dimethyl-3,4-dihydrocarbostyril-6-carbonyl)aminomethylphenyl]acrylic acid ethyl ester 
• 1616590-16-9 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-4-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 383665-96-1 (E)-3-[4-(tert-butoxycarbonylaminomethyl)phenyl]acrylic acid ethyl ester 
• 905456-93-1 C₄₁H₂₉N₅O₂ 
• 90561-76-5 N-(4-bromo-benzyl)-acetamide 
• 132273-07-5 2-(p-bromobenzyl)-1,1,3,3-tetramethyl-1,3-disilaisoindoline 
• 3959-07-7 4-Bromobenzylamine 

Relevant academic research and scientific papers

Five-membered heteroaromatic derivative, preparation method and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a five-membered heteroaromatic compound, a composition, a preparation method and application thereof. The compound or the composition can be used as an inhibitor of a retinoid-related orphan receptor [gamma]t (ROR [gamma]t). The invention also relates to a method for preparing the compound and the composition, and application of the compound and the composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

Nitrile Synthesis by Aerobic Oxidation of Primary Amines and in situ Generated Imines from Aldehydes and Ammonium Salt with Grubbs Catalyst

Herein, a Grubbs-catalyzed route for the synthesis of nitriles via the aerobic oxidation of primary amines is reported. This reaction accommodates a variety of substrates, including simple primary amines, sterically hindered β,β-disubstituted amines, allylamine, benzylamines, and α-amino esters. Reaction compatibility with various functionalities is also noted, particularly with alkenes, alkynes, halogens, esters, silyl ethers, and free hydroxyl groups. The nitriles were also synthesized via the oxidation of imines generated from aldehydes and NH4OAc in situ. (Figure presented.).

Alkoxide-Catalyzed Hydrosilylation of Cyclic Imides to Isoquinolines via Tandem Reduction and Rearrangement

An alkoxide-catalyzed hydrosilylation of cyclic imides to isoquinolines was realized via tandem reduction and rearrangement. Using TMSOK as the catalyst and (EtO)2MeSiH as the reductant, a series of cyclic imides containing different functional groups were reduced to the corresponding 3-aryl isoquinolines in moderate to good yields. The scenario of the reaction pathway was supposed to involve the reduction of imides to ω-hydroxylactams, which underwent rearrangement in the presence of a base catalyst, and then the carbonyl reduction, followed by siloxy elimination.

Mechanochemical N-alkylation of imides

The mechanochemical N-alkylation of imide derivatives was studied. Reactions under solvent-free conditions in a ball mill gave good yields and could be put in place of the classical solution conditions. The method is general and can be applied to various imides and alkyl halides. Phthalimides prepared under ball milling conditions were used in a mechanochemical Gabriel synthesis of amines by their reaction with 1,2-diaminoethane.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038 μM; HDAC2, 0.0082 μM; HDAC3, 0.015 μM; HDAC8, 0.0060 μM; HDAC4, 0.058 μM; HDAC9, 0.0052 μM; HDAC6, 0.058 μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

Generation and cross-coupling of benzyl and phthalimide-N-oxyl radicals in a cerium(IV) ammonium nitrate/N-hydroxyphthalimide/ArCH2R system

A method was developed for the cross-dehydrogenative coupling of alkylarenes and related compounds with N-hydroxyphthalimide (NHPI) using cerium(IV) ammonium nitrate (CAN) to prepare O-substituted NHPI derivatives. The characteristic feature of the reaction is that NHPI plays a dual role. Thus, in the presence of CAN, NHPI generates the phthalimide-N-oxyl (PINO) radical, which abstracts a hydrogen atom from the benzyl position to form a C-centered radical. The target oxidative cross-coupling product is formed mainly through the recombination of PINO with the C-centered radical. Therefore, NHPI serves as a mediator for the radical process and a reagent for the radical cross-coupling. The target products were obtained in yields from 35 to 80%.

Synthesis of unusual oxime ethers by reaction of tetranitromethane with B-alkylcatecholboranes

The reaction of tetranitromethane with B-alkylcatecholboranes leads to the formation of unusual dinitrooxime ethers. A tentative mechanism is provided, which suggests the involvement of extremely fast addition of alkyl radicals to tetranitromethane. The substitution of one of the nitro groups in the oxime ethers by nucleophiles (such as secondary amines, halogens and styrene) and by radicals generated from B-alkylcatecholboranes is reported.

Potent inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium: Charge-assisted hydrogen bonding

Improving inhibition: tRNA-Guanine transglycosylase (TGT) is a newly recognized target to reduce the pathogenicity of disease-causing Shigella bacteria. A potent family of inhibitors of this enzyme has been developed by structure-based design. Crystallographic data and pKa, analysis suggest that the aminoimidazole moiety of the central lin-benzoguanine scaffold is protonated and stabilization of the complexes results from charge-assisted hydrogen bonding. (Figure Presented).

METHOD FOR THE PRODUCTION OF LOSARTAN

The invention relates to a novel method for the production of losartan, an imidazol derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-]methyl}imidazol and the pharmacologically active salts thereof. The invention also relates to novel intermediate products which are suitable for the production of losartan, and to novel methods for the production of intermediate compounds which are suitable for the production of losartan. One aspect of the invention is a method for the production of a compound of general formula (I), which can arise as an intermediate step in the inventive representation of losartan.